16 completed, 2 unknown, 1 not yet recruiting, 1 terminated. 20 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 16, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow Livedoid Vasculopathy: new trials by email Literature Review of Livedoid Vasculopathy trials Research Report on Livedoid Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Civi Biopharma, Inc. | 198 | 2019-10-14 | 2025-05-25 |
| Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis BOTOX® solution, Placebo group - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 91 | 2018-10-15 | 2022-02-10 |
| Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Onabotulinumtoxin A, sterile saline solution - Scleroderma, Raynaud's Syndrome | Phase 3 | Completed | Johns Hopkins University | 40 | 2015-01-01 | 2016-12-22 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| "As Required" Oral Sildenafil in Raynaud's Phenomenon Sildenafil 40 mg, Sildenafil 80 mg, Placebo - Raynaud's Phenomenon | Phase 2 / Phase 3 | Completed | University Hospital, Grenoble | 41 | 2013-11-01 | 2016-01-18 |
| Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Sildenafil citrate, Placebo (Sugar pill) - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 3 | Completed | Federal University of São Paulo | 41 | 2011-04-01 | 2016-12-05 |
| Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Udenafil or Amlodipine - Raynaud Phenomenon | Phase 2 / Phase 3 | Completed | Seoul National University Hospital | 29 | 2011-01-01 | 2012-12-11 |
| A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Tadalafil, Placebo - Raynaud's Phenomenon, Digital Ulcers | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 66 | 2009-11-01 | 2010-05-10 |
| Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms 0.9% nitroglycerin in TAM cream, vehicle cream - Raynaud Disease | Phase 3 | Unknown | MediQuest Therapeutics | 100 | 2009-06-01 | 2010-07-20 |
| A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Nitroglycerin, Topical AmphiMatrix - Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma | Phase 3 | Unknown | MediQuest Therapeutics | 200 | 2007-12-01 | 2010-02-05 |
| Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Tadalafil - Raynaud Disease | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 25 | 2007-12-01 | 2013-03-22 |
| A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Fasudil - Raynaud, Scleroderma | Phase 3 | Completed | Johns Hopkins University | 17 | 2007-04-01 | 2014-11-04 |
| St. John's Wort in the Treatment of Raynaud's Phenomenon St. John's Wort, Lactose - Raynaud's Disease | Phase 3 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 20 | 2007-03-01 | 2009-07-14 |
| Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Topical AmphiMatrix with nitroglycerin (MQX-503) - Raynaud's Disease, Scleroderma | Phase 3 | Completed | MediQuest Therapeutics | 80 | 2006-12-01 | 2007-05-30 |
| Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome vardenafil, Placebo - Raynaud Syndrome | Phase 2 / Phase 3 | Completed | University of Cologne | 57 | 2006-11-01 | 2011-02-08 |
| Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Topical organogel with nitroglycerin - Raynaud's Disease | Phase 3 | Completed | MediQuest Therapeutics | 200 | 2005-12-01 | 2007-08-08 |
| Lab Study of MQX-503 in Treatment of Raynaud's topical organogel with nitroglycerin - Raynaud Disease, Raynaud Disease Secondary to Scleroderma | Phase 2 / Phase 3 | Completed | MediQuest Therapeutics | 36 | 2004-11-01 | 2007-05-30 |
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis iloprost - Systemic Sclerosis, Raynaud Disease | Phase 3 | Completed | National Center for Research Resources (NCRR) | 200 | 1995-12-01 | 2005-06-24 |
| Raynaud's Treatment Study (RTS) nifedipine, biofeedback (psychology), electromyography - Cardiovascular Diseases, Heart Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1992-09-01 | 2016-04-15 |
Raynaud Disease (20) · Scleroderma, Diffuse (10) · Scleroderma, Systemic (7) · Autoimmune Diseases (2) · Arthritis (1) · CREST Syndrome (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1) · Gangrene (1) · Heart Diseases (1) · Peripheral Vascular Diseases (1) · Rare Diseases (1) · Respiratory Tract Diseases (1) · Scleroderma, Limited (1) · Signs and Symptoms (1)
Embolism and Thrombosis (20) · Skin Diseases (20) · Skin Diseases, Vascular (20) · Skin and Connective Tissue Diseases (20) · Thrombosis (20) · Cardiovascular Diseases (19) · Peripheral Vascular Diseases (19) · Vascular Diseases (19) · Connective Tissue Diseases (14) · Scleroderma, Systemic (8) · Pathological Conditions, Signs and Symptoms (3) · Immune System Diseases (2) · Pathologic Processes (2) · Arterial Occlusive Diseases (1)
Nitroglycerin (5) · Botulinum Toxins (2) · Iloprost (2) · Sildenafil Citrate (2) · Tadalafil (2) · Amlodipine (1) · Biofeedback, Psychology (1) · Botulinum Toxins, Type A (1) · Hypericum extract LI 160 (1) · Lactose (1) · Long-Term Synaptic Depression (1) · Neurofeedback (1) · Nifedipine (1) · Sodium Chloride (1) · Sugars (1)
MediQuest Therapeutics (5) · Johns Hopkins University (2) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (2) · Assistance Publique - Hôpitaux de Paris (1) · Civi Biopharma, Inc. (1) · Federal University of São Paulo (1) · Jose Soberon, MD (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · National Center for Research Resources (NCRR) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Seoul National University Hospital (1) · University Hospital, Grenoble (1) · University Hospital, Toulouse (1) · University of Cologne (1)
United States (9) · France (3) · Canada (2) · Brazil (1) · Germany (1) · India (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Aman Sharma, MD (1) · Bruce Thompson (1) · Carin Dugowson, MD, MPH (1) · Darshan S Bhakuni, MD (1) · Eun Bong Lee, MD PhD (1) · Eun Young Lee, MD PhD (1) · Fernando V Andrigueti, MD (1) · Fredrick M Wigley, M.D. (1) · Jan Ohrstrom, PhD (1) · Janet E Pope, MD, MPH (1) · Jeff Gregory, MD (1) · Jin Kyun Park, MD (1) · Jose Soberon, MD (1) · Julie Malloizel-Delaunay, MD (1)
PMID 37929840, PMID 20837499, PMID 24352340, PMID 28426903, PMID 30383134, PMID 36066501
2005 (1)